When it comes to investing biotech stocks, it’s wise to focus on companies that have completed much of their drug development work. The closer a company gets to the finish line in the clinical-testing process, the less chance that a drug will fail — taking the company’s stock down sharply.#-ad_banner-#… Read More

Indicators are used by traders to forecast market moves and many have found success with these tools. I prefer simple chart reading, and one of the simplest ideas on charts is support and resistance. Support appears to keep prices from falling… Read More

After surging from less than $100 in early 2009 to a recent $670, Apple (Nasdaq: AAPL) has now an equal number of supporters and detractors.  Analysts who follow Apple know that it continues to churn out segment-busting products, and they note… Read More

Nathan Slaughter of Scarcity & Real Wealth made a great point in his most recent issue… Can you imagine the buzz if gold had spiked 60% during the past few months? Media outlets would be talking about it nonstop. Retirees would be urged to cash in… Read More

The recent bounce in volatility, a cost component in an option‘s price, has made premium-selling strategies more attractive. After a new five-year low in the CBOE Volatility Index… Read More

Pfizer’s (NYSE: PFE) 2004 peak approached $40 before a multi-year decline. But shares have been on a strong recovery from 2009 lows below $12 a share to nearly double that price today. The combination of the powerful trend and low volatility… Read More

As we head into the final trimester of 2012, it’s time to take a fresh look at where we stand in terms of the stock market and the economy. So far this… Read More

Do you want to make a lot of money investing in commodities? Then oil and gas producers are a great place to start. But odds are, you’re probably not going to do it with global behemoths like Chevron (NYSE: CVX) and Exxon-Mobil (NYSE: XOM).#-ad_banner-# Don’t get me… Read More

It’s not every day a quality dividend stock yielding almost 9% goes on sale at almost 20% off. But that’s the deal that readers of High-Yield International were alerted to three weeks ago. And it’s not too late… Read More

Today, I want to cover a popular market ETF that is a strong buy based on a momentum indicator that most traders ignore and a… Read More